{"id":66929,"date":"2026-06-01T14:14:46","date_gmt":"2026-06-01T06:14:46","guid":{"rendered":"https:\/\/flcube.com\/?p=66929"},"modified":"2026-06-01T14:14:47","modified_gmt":"2026-06-01T06:14:47","slug":"astrazenecas-imfinzi-bcg-combination-approved-for-high-risk-non-muscle-invasive-bladder-cancer-in-us","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66929","title":{"rendered":"AstraZeneca’s IMFINZI-BCG Combination Approved for High-Risk Non-Muscle-Invasive Bladder Cancer in US"},"content":{"rendered":"\n

AstraZeneca (NASDAQ: AZN)<\/a><\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved IMFINZI (durvalumab)<\/strong>, its PD-L1 antibody<\/strong>, in combination with Bacillus Calmette-Gu\u00e9rin (BCG) induction and maintenance therapy<\/strong> for the treatment of adult patients with BCG-na\u00efve, high-risk non-muscle-invasive bladder cancer (NMIBC)<\/strong>. The approval, supported by the Phase 3 POTOMAC trial<\/strong>, demonstrated a 32% reduction in the risk of high-risk disease recurrence, progression, or death<\/strong> compared to BCG alone, marking the first immunotherapy combination approved for this indication.<\/p>\n\n\n\n

Regulatory Approval Details<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>FDA (United States)<\/td><\/tr>
Approval Type<\/strong><\/td>Full approval<\/td><\/tr>
Company<\/strong><\/td>AstraZeneca (NASDAQ: AZN)<\/td><\/tr>
Drug Combination<\/strong><\/td>IMFINZI (durvalumab) + BCG induction and maintenance<\/td><\/tr>
Indication<\/strong><\/td>BCG-na\u00efve, high-risk non-muscle-invasive bladder cancer (NMIBC)<\/td><\/tr>
Approval Date<\/strong><\/td>28 May 2026<\/td><\/tr>
Supporting Trial<\/strong><\/td>Phase 3 POTOMAC study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Trial Results<\/h2>\n\n\n\n
Endpoint<\/th>Result (IMFINZI + BCG)<\/th>Comparator (BCG alone)<\/th>Benefit<\/th><\/tr><\/thead>
Primary Endpoint<\/strong><\/td>Recurrence-free survival (composite of recurrence, progression, or death)<\/td>BCG alone<\/td>32% risk reduction<\/strong> (HR: 0.68; p<0.001)<\/td><\/tr>
Treatment Duration<\/strong><\/td>One year of IMFINZI added to standard BCG regimen<\/td>Standard BCG regimen<\/td>Enhanced efficacy without compromising safety<\/td><\/tr>
Patient Population<\/strong><\/td>BCG-na\u00efve, high-risk NMIBC<\/td>Same population<\/td>Addresses significant unmet need in early-stage disease<\/td><\/tr>
Safety Profile<\/strong><\/td>Consistent with known profiles of individual agents<\/td>Not applicable<\/td>No new safety signals<\/strong> identified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context & Unmet Need<\/h2>\n\n\n\n

Non-muscle-invasive bladder cancer (NMIBC)<\/strong> accounts for approximately 75% of newly diagnosed bladder cancer cases<\/strong>, with high-risk NMIBC<\/strong> carrying a substantial risk of progression to muscle-invasive disease requiring radical cystectomy (bladder removal). Despite being the standard of care for decades, BCG monotherapy fails in up to 40% of high-risk patients<\/strong>, creating an urgent need for more effective treatment strategies.<\/p>\n\n\n\n

The IMFINZI-BCG combination represents a paradigm shift by:<\/p>\n\n\n\n